Nicergoline is an ergoloid mesylate derivative used to treat senile dementia and other disorders with vascular origins. It has been found to increase mental agility and enhance clarity and perception. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs.
Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.
It is marketed under the trade name Sermion.
Nicergoline has alpha-adrenolytic action which activates the brain's metabolism and improves arterial flow, lowers vascular resistance and improves the use of glucose and oxygen. Furthermore, it is known that Nicergoline inhibits platelet aggregation. Studies have shown that Nicergoline also increases nerve growth factor in the aged brain.
Nicerogline is used in the following cases:
Dosages for known conditions are usually administered at 5-10mg three times a day, however anti-aging preventative purposes may want to consider 5mg once or twice a day more adequate.
Persons suffering from acute bleeding, myocardial infarction (heart conditions), hypertension, bradycardia or using alpha or beta receptor agonists should consult with their physician before use. Although toxicology studies have not shown nicergoline to have any teratogenic effect, the use of this medicine during pregnancy should be limited to those cases where it is absolutely necessary.
Antinociceptive and hypothermic evaluation of the leaf essential oil and isolated terpenoids from Eugenia uniflova L. (Brazilian Pitanga).(Report)
Oct 01, 2009; Abstract Eugenia uniflora L. (Myrtaceae), known as Brazilian cherry tree, is a fruity tree spread all over Brazil used in popular...
Study results from University of Santiago of Compostela, Faculty of Medicine broaden understanding of Parkinson disease.
Aug 11, 2010; Current study results from the report, 'Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal...